myopathy is a broad category of neuromuscular diseases in which the primary defect is within the muscle fiber itself, leading to muscular weakness, cramping, stiffness, or spasm. It is clinically distinguished from neuropathy, where muscle weakness is secondary to nerve damage or denervation. The underlying pathological mechanisms can be genetic (such as mutations affecting muscle structural proteins), inflammatory (autoimmune attack on muscle fibers), metabolic (defects in glycogen or lipid metabolism), or toxic (drug-induced damage). While some myopathies are congenital and present in infancy (e.g., congenital myopathies, muscular dystrophies), many are acquired and pathological (e.g., statin-induced myopathy, polymyositis). The clinically relevant subtypes most commonly encountered in coding include toxic/drug-induced myopathy (G72.0), inflammatory myopathies like polymyositis (M33.2x), and unspecified myopathy (G72.9). myopathy is commonly confused with myalgia; however, myalgia refers strictly to muscle pain, whereas myopathy indicates actual structural or functional disease of the muscle tissue, which may or may not be painful.
The word entered English in the 1840s as myopathy (noun), borrowed from French myopathie, from Modern Latin myopathia, from Greek mys + pathos — literally “muscle disease.” The adjective form myopathic appeared shortly thereafter to describe clinical findings (e.g., “myopathic changes on EMG”). The root mys- (“muscle”) connects myopathy to the entire -MYO FAMILY: myocardium (muscle + heart → heart muscle), myositis (muscle + inflammation → inflammation of muscle), and myalgia (muscle pain). The suffix -pathy is highly productive in medical terminology, appearing in numerous disease states such as neuropathy, cardiomyopathy, and retinopathy.
🔀 ALIASES / ALTERNATE TERMS
Myopathic(adjective form — e.g., “myopathic motor unit potentials,” “myopathic gait”)
Muscle disease(lay and clinical term; often used broadly in primary care or pediatrics)
Myositis(inflammatory form of the condition; characterized by muscle inflammation and weakness)
Primary muscle disorder(clinical synonym used in neurology/PMR to distinguish from neurogenic weakness)
Sarcopenia(age- or immobility-related form of muscle loss and weakness; M62.84)
Cachexia(systemic wasting syndrome, often malignancy- or chronic disease-related, involving severe myopathy)
Toxic myopathy(define by cause — e.g., due to statins, corticosteroids, or alcohol)
Metabolic myopathy(define by cause — e.g., from glycogen storage diseases like Pompe disease)
Congenital myopathy(genetic/inherited form with ICD-10-CM code range — e.g., nemaline myopathy; G71.2x)
Endocrine myopathy(organ/systemic-specific form with ICD-10-CM code range — e.g., thyrotoxic myopathy; G73.7)
Steroid myopathy(iatrogenic form with ICD-10-CM code range — e.g., prolonged corticosteroid use; G72.0)
Critical illness myopathy(ICU-acquired form with ICD-10-CM code range — e.g., severe weakness post-ventilation; G72.81)
🔗 RELATED TERMS
Neuropathy — the opposite/counterpart of myopathy; disease of the peripheral nerves causing weakness via denervation, distinguished from myopathy by sensory loss and distal (rather than proximal) weakness.
Myalgia — shares the myo- root; muscle pain without necessarily involving structural muscle disease or weakness.
Rhabdomyolysis — severe, rapid breakdown of skeletal muscle tissue leading to myoglobinuria and potential acute kidney injury; M62.82.
Fibromyalgia — complex chronic pain syndrome overlapping with myalgia and fatigue, but without the structural muscle fiber destruction seen in true myopathies.
Denervation — loss of nerve supply to a muscle, the physiological mechanism causing neurogenic muscle atrophy (as opposed to primary myopathic atrophy).
Myotrophic — adjective describing hormonal or nutritional inputs that sustain or promote muscle tissue growth.
Apoptosis — programmed cellular death underlying certain pathological forms of muscle wasting and genetic myopathies.
Muscular Dystrophy — genetic, progressive disease entity defined by this term; includes Duchenne and Becker types (G71.0-).
Polymyositis — inflammatory disease entity defined by this term; autoimmune attack on proximal musculature (M33.2x).
Cardiomyopathy — clinical entity defined by this term at a specific anatomic site; disease of the heart muscle tissue.
Needle electromyography, each extremity, with related paraspinal areas, when performed, done with nerve conduction, amplitude and latency/velocity study; limited
Needle electromyography, each extremity, with related paraspinal areas, when performed, done with nerve conduction, amplitude and latency/velocity study; complete
Therapeutic procedure, 1 or more areas, each 15 minutes; neuromuscular reeducation of movement, balance, coordination, kinesthetic sense, posture, and/or proprioception for sitting and/or standing activities
⚠️ Coding Note: For inpatient profee coding, always sequence the underlying cause first if the myopathy is secondary to another condition or a toxin. For example, if coding drug-induced myopathy (G72.0), you must first code the appropriate T-code (e.g., T46.6X5A for adverse effect of statins) to identify the drug. A common undercoding issue occurs when providers document “generalized weakness” or “deconditioning” when the clinical picture and CK levels actually support a specific myopathy or rhabdomyolysis; this should prompt a query for clarification. When billing EMG services (95860-95864) in the inpatient setting, remember to append modifier -26 (Professional Component) if the equipment is owned by the hospital. Finally, ensure you are not billing standalone EMG codes (95860-95864) alongside Nerve Conduction Studies (NCS) on the same day; use the add-on codes (95885, 95886) when EMG and NCS are performed concurrently.